Episode Description
Dr. Jonathan Strosberg, section chief of the Neuroendocrine Tumor Division of the Moffitt Cancer Center, discusses the recent FDA approval of Lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

























